Mustafa Gürbüz

12PUBLICATIONS
112CO-AUTHORS
Predictive and prognostic markersHaematological tumoursMedical biochemistry - lipidsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 26, 2026
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu

|Mar 19, 2026
Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors.

Mustafa Gürbüz, Deniz Tural, Timuçin Çil

|Aug 28, 2025
Prognostic Value of Metabolic Tumor Volume and Heterogeneity Index in Diffuse Large B-Cell Lymphoma.

Ali Alper Solmaz, Ilhan Birsenogul, Aygul Polat Kelle

|May 06, 2025
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Sedat Yıldırım, Tugba Başoğlu, Akif Doğan

|Nov 27, 2024
Rectal Cancer and Lateral Lymph Node Staging: Interobserver Agreement and Success in Predicting Locoregional Recurrence.

Hüseyin Akkaya, Okan Dilek, Selim Özdemir

|Dec 23, 2022
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.

Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici

Pageof 2

Frequent Collaborators

3 joint publications

Havva Yeşil Çınkır

2 joint publications

Ali Alkan

2 joint publications

Hatime Arzu Yaşar

2 joint publications

Serdar Turhal